In patients predisposed to develop sJIA-LD, biologic drugs could promote CD4+ cell differentiation into Th1 cells rather than Th17 cells (induced by high levels of IL-1 and IL-6 usually found in sJIA), with a consequent increase in IFNγ production [24]. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.